

CURRICULUM VITAE

DENNIS RASMUSSEN

1. PERSONAL DATA

2. EDUCATION

- 1974 B.S. University of Wisconsin, Eau Claire
Zoology/Chemistry
- 1980 Ph.D. Purdue University
Interdisciplinary Neuroscience Program

3. POSTGRADUATE TRAINING

- 1981-1983 Postdoctoral Scholar
Neuroendocrinology
Department of Reproductive Medicine
University of California, San Diego

4. FACULTY POSITIONS HELD

- 1983-1984 Assistant Research Endocrinologist
Department of Reproductive Medicine
University of California, San Diego
- 1984-1990 Assistant Professor
Department of Reproductive Medicine
University of California, San Diego
- 1990-1994 Associate Professor
Department of Reproductive Medicine
University of California, San Diego
- 1994-2001 Research Associate Professor
Department of Medicine
University of Washington, Seattle
- 1994-pres Health Science Specialist, VA Puget Sound Health Care
System
- 1994-pres Research Affiliate
Alcohol and Drug Abuse Institute
University of Washington, Seattle
- 2001-2004 Research Associate Professor
Department of Psychiatry and Behavioral Sciences
University of Washington, Seattle
- 2004-pres Research Professor

Department of Psychiatry and Behavioral Sciences
University of Washington, Seattle

2007-pres Associate Director for Research
VA VISN 20 Northwest Network Mental Illness Research, Education
and Clinical Center

5. HOSPITAL POSITIONS HELD

None

6. HONORS

Phi Kappa Phi National Honor Society, inducted in 1973
B.S. Cum Laude, 1974
David Ross Fellowship, 1978-1979
Alpha Zeta Honorary, inducted in 1979
NIH National Research Service Award, 1981-1982
Serono In-Training Award, 1983
Mellon Foundation Faculty Scholar Award, 1984-1985
Glenn Foundation Endocrinology and Aging Award, 1998

7. BOARD CERTIFICATION

N/A

8. LICENSE TO PRACTICE

N/A

9. PROFESSIONAL ORGANIZATIONS

Society for Neuroscience
The Endocrine Society
Research Society on Alcoholism
International Society of Neuroendocrinology
International Society of Psychoneuroendocrinology
International Society for Brain Research on Alcoholism

10. TEACHING

1986 - 1993: UCSD Physiology/Pharmacology 239, Reprod. Med. 229: "Practical Design and Evaluation of Biomedical Research." Sole instructor.

1987 – 1993, alternating years: UCSD Reproductive Medicine 227: "Neuroendocrinology." Team-taught; responsible for 15% of lectures.

1988, 1989: UCSD Fifth College 90: "Mind-body integration: brain, endocrine, immune and behavioral interactions." Undergraduate seminar course co-taught with one other instructor, with equally shared responsibilities.

1989 - 1993, alternating years: UCSD Neuroscience 234: "Molecular and Cellular Neurochemistry." Team-taught; responsible for 12.5% of lectures.

1994 - pres: ad hoc lecturing at American Lake and Seattle VA Medical Centers and the University of Washington Departments of Medicine, Obstetrics and Gynecology, and Psychiatry and Behavioral Sciences; active mentoring of MIRECC psychiatrist and psychologist fellows in behavioral research methodology and data analysis, including didactic teaching of a range of topics in neuroscience and experimental design; membership on junior faculty mentoring committees.

11. EDITORIAL RESPONSIBILITIES

Frequent ad hoc reviewing: Endocrinology, Neuroendocrinology, Alcoholism: Clinical and Experimental Research, Alcohol, Journal of Pineal Research, Neuropsychopharmacology. Others on less frequent basis.

12. SPECIAL NATIONAL RESPONSIBILITIES

- 1992-pres. Ad hoc grant proposal reviewing for the National Science Foundation, USDA, Pew Foundation, Life and Health Insurance Medical Research Fund, Searle Foundation, Laylor Foundation
- 1999-pres NIH Special Emphasis Panels (reviews of individual investigator, center, INIA consortium, supplement, and fellowship applications; 14 panels total): ZAA1 E 02 , ZAA1 AA 02, ZRG1 IFCN, ZAA1 AA 76, ZRG1 IFCNI 03, ZAA1 CC 26, ZZAA1 DD 23, ZAA1 DD 33, ZAA1 DD 62, ZAA1 DD 71, ZAA1 SRC(99), ZAA1 CC 15 1, ZAA1 JJ 14L, ZRG1 IFCN-H(95).
- 2004 VA Merit Review Subcommittee for Neurobiology-A (review of grant proposals)
- 2006-2007Ad hoc: Neurotoxicity and Alcohol (NAL) Study Section; Integrative, Functional and Cognitive Neuroscience IRG; CSR; NIH
- 2007-pres Member: Neurotoxicity and Alcohol (NAL) Study Section; Integrative, Functional and Cognitive Neuroscience IRG; CSR; NIH
- 2007 Dept of Defense Congressionally Directed Medical Research Program (DCMRP) Peer Review Panel: PTSD Neurobiology and Genetics #1

13. SPECIAL LOCAL RESPONSIBILITIES

- 1984-1993Member, UCSD Academic Senate
- 1985-1993Member, UCSD Neurosciences Graduate Program
- 1987-1993Fellows Selection Committee, Department of Reproductive Medicine, UCSD School of Medicine
- 1988-1989Coordinator, Research Seminar Series, Department of Reproductive Medicine, UCSD School of Medicine
- 1988-1989Curriculum Consultant for the California Department of Education, Accrediting Commission.
- 1988-1993Departmental Representative, Preclinical Faculty Steering Committee, UCSD School of Medicine
- 1988-1993Treasurer, Preclinical Faculty Steering Committee, UCSD School of Medicine.
- 1989-1991Recruitment and Admissions Committee, UCSD School of Medicine.
- 1990-1993UCSD Academic Senate Committee on Research, Health Sciences Subcommittee
- 1990-1993Faculty Research Committee, UCSD School of Medicine

1990-1991 Coordinator, Research Seminar Series, Department of Reproductive Medicine, UCSD School of Medicine

1991-1993 Searle Scholar nomination review committee, UCSD School of Medicine

1991-1993 Pew Scholar nomination review committee, UCSD School of Medicine

1991-1993 Student Affairs Committee, UCSD School of Medicine

1992-1993 Neurosciences Graduate Program Minor Proposition Examination Committee, UCSD School of Medicine

1992-1993 Faculty Promotions Review Committee, Department of Reproductive Medicine, UCSD School of Medicine

1993 Life and Health Insurance Medical Research Fund Biomedical Research Grant review committee, UCSD School of Medicine

1993 Chairman, UCSD Academic Senate Committee on Research, Health Sciences Subcommittee

1994 Lecturer, VA Women's Health Symposium, Tacoma, WA

1994-1996 Coordinator, Research Conferences, Research Service, American Lake VA Medical Center

1994-1995 Acting Associate Chief of Staff for Research on an ad hoc basis in the absence of the ACOS for R&D, American Lake VA Medical Center

1994-1995 Research and Development Committee, American Lake VA Medical Center

1995-1996 Chairman, Research and Development Committee, American Lake VA Medical Center

1996 Seattle/American Lake VAMC Research and Development merger working group.

1996-1997 VA Puget Sound Health Care System (VAPSHCS) Research and Development Committee

1996-2002 Acting Deputy Associate Chief of Staff for Research and Development on an ad hoc basis in the absence of the Deputy ACOS for R&D, VAPSHCS American Lake Division

1998-2000 VAPSHCS Research and Development Animal Studies Subcommittee

2003 Chairman, VAPSHCS Research and Development Equipment ad hoc subcommittee

1999-2002 University of Washington (UW) School of Medicine Admissions Committee

2000-2002 VAPSHCS Research and Development Space Subcommittee

2002-2004 UW Alcohol and Drug Abuse Institute (ADAI) Grant Program review committee

2002-2004 Chairman, VAPSHCS Institutional Animal Care and Use Committee

2002-2004 VAPSHCS Research and Development Committee

2003-2004 Neuroscience Faculty Search Committee, Department of Psychiatry and Behavioral Sciences, UW

2004-pres Resident Applicant Interviewing Committee, Department of Psychiatry and Behavioral Sciences, UW

2004-2006 Elected member, UW Faculty Senate

2004-2007 Elected member, Council On Research and Graduate Education, UW School of Medicine

2004-2005 Addictions/Trauma Workgroup, Department of Psychiatry and Behavioral Sciences, UW

2005-2007 UW Alcohol and Drug Abuse Institute (ADAI) Small Grant Program review committee

2005 Co-chair, VAPSHCS Building 13/34 Advisory Committee

2005-2008 UW Faculty Council on Student Affairs

2006-pres Chairman, VAPSHCS Research and Development Space Subcommittee

2006 UW School of Medicine CORGE Subcommittee for reviewing Provost Bridge Funding proposals

2006-2009 UW Dept. of Psychiatry Faculty mentorship committee: Paul Philips

2006-2009 VA Career Development Award mentorship committee: Valerie Olson
2007 UW Department of Psychiatry Research Task Force
2007 UW Faculty Councils Nominating Committee
2009 Faculty Promotions Review Committee, Department of Psychiatry
and Behavioral Sciences, UW
2009-pres Elected member, Council On Research and Graduate Education, UW
School of Medicine
2009-pres VAPSHCS Research and Development Scientific Review
Subcommittee

14. RESEARCH FUNDING

NIH National Research Service Award, 1981-1983; \$38,200. Postdoctoral support.

Mellon Foundation Young Investigator in Reproductive Science Award, 8/83-6/86;
\$255,000. Role: Principal Investigator.

NIH/NICHD R01 HD22608 "Regulation of hypothalamic pulsatile GnRH
secretion", 12/86-6/90; \$274,139 direct costs. Role: Principal Investigator.

NIH/NICHD P50 HD12303 Unit 4 "POMC peptides in the neuroendocrinology of
reproduction" 12/87-4/93; \$320,696 direct costs. Role: Principal Investigator.

U.C. Tobacco Related Disease Research Program 2IT0040 "A hypothalamic
mechanism of nicotine reward and addiction", 7/91-6/92; \$62,060 direct costs. Role:
Principal Investigator.

VA Research Advisory Group "Opiomelanocortinerbic regulation and integration in
drug abuse: cocaine." 10/94-9/95; \$55,200 direct costs. Role: Principal
Investigator.

NIH R01 AA10567 "Alcohol Effects on Opiomelanocortinerbic regulation" 7/01/94-
6/30/97; \$156,674 direct costs. Role: Principal Investigator.

UW Alcohol and Drug Abuse Institute, "A New Model for Investigating
Developmental Responses to Fetal Drug Exposure: Prenatal Alcohol Effects on
Brain Opiomelanocortinerbic Regulation." 02/15/95-02/14/98; \$14,994 direct costs.
Role: Principal Investigator.

Supplement to NIH R01 AA10567 "Alcohol Effects on Opiomelanocortinerbic
regulation" 07/01/97-06/30/98; \$52,381 direct costs. Role: Principal Investigator

NIH R01 AA10567 "Alcohol Effects on Opiomelanocortinerbic Regulation" 04/01/98-
03/31/04; \$453,006 direct costs. Role: Principal Investigator.

NIH R21 DK61766 "Metabolic Changes During Aging: A Role for Melatonin"
07/01/02-06/30/04; \$200,000 direct costs. Role: Principal Investigator.

NIH R01 AA013881-01 "Neuroendocrine Therapy of Alcohol Abuse" 05/01/03-
04/30/07 (extended to 04/30/09); \$600,000 direct costs. Role: Principal
Investigator.

NIH 2R01 AA010567-07A2 "Alcohol Effects on Opiomelanocortinergic Regulation", 04/01/05-03/31/10; \$1,000,000 direct costs. Role: Principal Investigator.

NIH 1P20AA017839-01 "Center for Neuroregulation in Alcohol Dependence (CeNiAD). Exploratory Project 1: "Effects of Pharmacologic Reduction of Noradrenergic Signaling on Alcohol Ingestion by Alcohol Preferring (P) Rats" 09/30/09-08/31/11; \$983,591 direct costs for overall Center (PI: Andrew Saxon), \$183,975 direct costs for Exploratory Project 1. Role: Project Leader for Exploratory Project 1 and Associate Director for overall Center.

NIH 1R01AA018604-01A1 "Noradrenergic Agents as Potential New Pharmacotherapies for Alcohol Drinking" 03/01/10-02/28/15; \$1,185,880 direct costs. Role: Principal Investigator (Contact). This is a multiple PI project administered by the Seattle Institute for Biomedical and Clinical Research; the co-PI is Dr. Jan Froehlich of Indiana University.

15. BIBLIOGRAPHY

a) Peer reviewed publications of original work

1. **Rasmussen DD**, Jacobs W, Kissinger PT, Malven PV 1981 Plasma luteinizing hormone in ovariectomized rats following pharmacologic manipulation of endogenous brain serotonin. *Brain Res.* 229:230-235
2. **Rasmussen DD**, Malven PV 1981 Chronic recording of multiple-unit activity from the brain of conscious sheep. *Brain Res. Bull* 7:163-167
3. **Rasmussen DD**, Malven PV 1981 Relationship between rhythmic motor activity and plasma luteinizing hormone in ovariectomized sheep. *Neuroendocrinology* 32:364-369
4. **Rasmussen DD**, Malven PV 1982 Characterization of cephalic arteriovenous LH differences by continuous sampling in ovariectomized sheep. *Neuroendocrinology* 34:415-420
5. Ishizuka B, Wilkes MM, Stewart RD, **Rasmussen DD**, Yen SSC 1982 Increase of beta-endorphin concentrations in the plasma and pituitary neurointermediate lobe of the rat on the afternoon of proestrus. *Life Sci.* 31:2113-2120
6. **Rasmussen DD**, Yen SSC 1983 Progesterone and 20 alpha-hydroxyprogesterone stimulate the in vitro release of GnRH by the isolated mediobasal hypothalamus. *Life Sci.* 32:1523-1530
7. **Rasmussen DD**, Malven PV 1983 Effects of confinement stress on episodic secretion of LH in ovariectomized sheep. *Neuroendocrinology* 36:392-396
8. **Rasmussen DD**, Ishizuka B, Quigley ME, Yen SSC 1983 Effects of tyrosine and tryptophan ingestion on plasma catecholamine and 3,4 dihydroxyphenylacetic acid concentrations. *J. Clin. Endocrin. Metab.* 57:760-76
9. **Rasmussen DD**, Liu JH, Yen SSC 1983 Endogenous opioid regulation of GnRH release from the human mediobasal hypothalamus in vitro. *J. Clin. Endocrin. Metab.* 57:881-884

10. **Rasmussen DD** 1986 Physiological interactions of the basic rest-activity cycle of the brain: pulsatile luteinizing hormone secretion as a model. *Psychoneuroendocrinology* 11:380-405
11. **Rasmussen DD**, Liu LH, Wolf P, Yen SSC 1986 GnRH neurosecretion in the human hypothalamus: in vitro regulation by dopamine. *J. Clin. Endocrinol. Metab.* 62:479-483
12. Gambacciani M, Yen SSC, **Rasmussen DD** 1986 GnRH release from the mediobasal hypothalamus: in vitro regulation by oxytocin. *Neuroendocrinology* 42:181-183
13. Gambacciani M, Yen SSC, **Rasmussen DD** 1986 GnRH release from the mediobasal hypothalamus: in vitro inhibition by corticotrophin releasing factor. *Neuroendocrinology* 43:533-536
14. Suh BY, Liu JH, **Rasmussen DD**, Gibbs DM, Steinberg J, Yen SSC 1986 The role of oxytocin in the modulation of ACTH release in women. *Neuroendocrinology* 44:309-313
15. **Rasmussen DD** 1986 New concepts in the regulation of hypothalamic gonadotropin releasing hormone (GnRH) secretion. *J. Endocrinol. Invest.* 9:427-437
16. **Rasmussen DD**, Liu JH, Swartz WH, Tueros VS, Yen SSC 1986 Human fetal hypothalamic GnRH neurosecretion: dopaminergic regulation in vitro. *Clin. Endo.* 25:127-132
17. **Rasmussen DD**, Liu JH, Wolf P, Yen SSC 1987 Neurosecretion of human hypothalamic immunoreactive beta-endorphin: in vitro regulation by dopamine. *Neuroendocrinology* 45:197-200
18. Liu JH, **Rasmussen DD**, Rivier J, Vale W, Yen SSC. 1987 Pituitary responses to synthetic corticotropin-releasing hormone: absence of modulatory effects by estrogen and progesterone. *Am. J. Obstet. Gynecol.* 157:1387-1391.
19. Liu JH, Kazer RR, **Rasmussen DD** 1987 Characterization of the 24-hour secretion patterns of adrenocorticotropin and cortisol in women with Cushing's Disease. *J. Clin. Endocrinol. Metab.* 64:1027-1035
20. Gambacciani M, Liu JH, Swartz WH, Tueros VS, Yen SSC, **Rasmussen DD** 1987 Intrinsic pulsatility of LH release from the human pituitary in vitro. *Neuroendocrinology* 45:402-406
21. Gambacciani M, Liu JH, Swartz WH, Tueros VS, **Rasmussen DD**, Yen SSC 1987 Intrinsic pulsatility of ACTH release from the human pituitary in vitro. *Clin. Endo.* 26:557-563
22. Gambacciani M, Yen SSC, **Rasmussen DD**. 1988 GnRH stimulates ACTH and immunoreactive beta-endorphin release from the rat pituitary in vitro. *Life Sci.* 43:755-760.
23. Rossmannith WG, Gambacciani M, Liu JH, Swartz WH, Tueros VS, Yen SSC, **Rasmussen DD**. 1988 Pulsatile beta-endorphin release from the human pituitary in vitro. *Gynecol. Endocrinol.* 2:1-10.
24. Mortola JF, Liu JH, Gillin JC, **Rasmussen DD**, Yen SSC. 1987 Pulsatile rhythms of ACTH and cortisol in women with endogenous depression: evidence for increased ACTH pulse frequency. *J. Clin. Endocrinol. Metab.* 65:962-968.

25. **Rasmussen DD**, Gambacciani M, Swartz WH, Tueros VS, Yen SSC. 1989 Pulsatile GnRH release from the human mediobasal hypothalamus in vitro: opiate receptor mediated suppression. *Neuroendocrinology* 49:150-156.
26. **Rasmussen DD**, Kennedy BP, Ziegler MG, Nett TM 1988 Endogenous opioid inhibition and facilitation of GnRH release from the median eminence in vitro: potential role of catecholamines. *Endocrinology* 123:2916-2921.
27. Mortola JF, **Rasmussen DD**, Yen SSC 1989 Alterations of the adrenocorticotropin-cortisol axis in normal weight bulimic women: evidence for a central mechanism. *J. Clin. Endocrinol. Metab.* 68:517-522.
28. Rossmanith WG, Yen SSC, **Rasmussen DD**. 1990 Synchronous pulsatile release of LH and immunoreactive beta-endorphin from the human pituitary in vitro. *J. Neuroendocrinol.* 2:91-94.
29. Rossmanith WG, Swartz WH, Tueros VR, Yen SSC, **Rasmussen DD** 1990 Pulsatile GnRH-stimulated LH release from the human fetal pituitary in vitro: sex-associated differences. *Clin. Endocrinol.* 33:719-727.
30. **Rasmussen DD** 1991 High post-ovariectomy LH levels are not due to decreased opioid inhibition of GnRH. *Brain Res. Bull.* 26:663-666.
31. **Rasmussen DD** 1991 Dopamine/endorphin interaction in the regulation of GnRH secretion. *New Trends Gynaecol.Obst.* 7:335-343.
32. **Rasmussen DD** 1991 The interaction between mediobasohypothalamic dopaminergic and endorphinergic neuronal systems as a key regulator of reproduction: an hypothesis. *J.Endocrinol.Invest.* 14:323-352.
33. **Rasmussen DD** 1991 Dopamine-opioid interactions in the regulation of hypothalamic GnRH secretion. *Neuroendocrinol. Lett.* 13:419-424.
34. **Rasmussen DD** 1992 Human hypothalamic and pituitary neuroendocrine function during in vitro perfusion. *Prog.Brain Res.* 93:69-82.
35. **Rasmussen DD** 1992 A dopaminergic mechanism for estrogen regulation of hypothalamic endorphinergic activity? *New Dev.Biosci.* 6:101-108.
36. **Rasmussen DD**, Jakubowski M, Allen DL, Roberts JL 1992 Positive correlation between proopiomelanocortin and tyrosine hydroxylase mRNA levels in the mediobasohypothalamus of ovariectomized rats: response to estradiol replacement and withdrawal. *Neuroendocrinology* 56:285-294.
37. **Rasmussen DD** 1993 Diurnal modulation of rat hypothalamic gonadotropin-releasing hormone (GnRH) release by melatonin in vitro. *J.Endocrinol.Invest.* 16:1-7.
38. **Rasmussen DD** 1993 Episodic gonadotropin-releasing hormone release from the rat isolated median eminence in vitro. *Neuroendocrinology* 58:511-518.
39. **Rasmussen DD** 1998 Effects of chronic nicotine treatment and withdrawal on neuroendocrine regulation and mediobasohypothalamic proopiomelanocortin and tyrosine hydroxylase mRNA contents. *Psychoneuroendocrinology* 23:245-259.

40. **Rasmussen DD**, Bryant CA, Boldt BM, Colasurdo EA, Levin N, Wilkinson CW 1998 Acute alcohol effects on opiomelanocortinergic regulation. *Alcohol.Clin.Exp.Res.* 22:789-801.
41. **Rasmussen DD**, Boldt BM, Wilkinson CW, Yellon SM, Matsumoto AM 1999 Daily melatonin administration at middle age suppresses male rat visceral fat, plasma leptin, and plasma insulin to youthful levels. *Endocrinology* 140:1009-1012.
42. Szot P, White SS, Veith RC, **Rasmussen DD** 1999 Reduced dopamine transporter (DAT) mRNA in the ventral tegmental area (VTA) of adult male rats exposed prenatally to ethanol. *Alcohol.Clin.Exp.Res.* 23:1643-1649.
43. Wolden-Hanson T, Mitton DR, McCants RL, Yellon SM, Wilkinson CW, Matsumoto AM, **Rasmussen DD** 2000 Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat. *Endocrinology* 141:487-497.
44. **Rasmussen DD**, Boldt BM, Bryant CA, Mitton SR, Larsen SA, Wilkinson CW 2000 Chronic daily ethanol and withdrawal: 1. Long-term changes in the hypothalamo-pituitary-adrenal axis. *Alcohol.Clin.Exp.Res.* 24:1836-1849.
45. **Rasmussen DD**, Mitton DR, Larsen SA, Yellon SM 2001 Aging-dependent changes in the effect of daily melatonin supplementation on rat metabolic and behavioral responses. *J.Pineal Res.* 31:89-94.
46. **Rasmussen DD**, Mitton DR, Green J, Puchalski S 2001 Chronic daily ethanol and withdrawal: 2. Behavioral changes during prolonged abstinence. *Alcohol.Clin.Exp.Res.* 25:999-1005.
47. **Rasmussen DD**, Boldt BM, Wilkinson CW, Mitton DR 2002 Chronic daily ethanol and withdrawal: 3. Forebrain proopiomelanocortin gene expression and implications for dependence, relapse and deprivation effect. *Alcohol.Clin.Exp.Res.* 26:535-546.
48. **Rasmussen DD**, Marck BT, Boldt BM, Yellon SM, Matsumoto AM 2003 Suppression of hypothalamic pro-opiomelanocortin (POMC) gene expression by daily melatonin supplementation in aging rats. *J.Pineal Res.* 34:127-133.
49. Puchalski SS, Green JN, Mitton DR, **Rasmussen DD** 2003 Melatonin effect on metabolism independent of gonad function. *Endocrine* 21:169-173.
50. Puchalski SS, Green JN, **Rasmussen DD** 2003 Melatonin effect on rat body weight regulation in response to high-fat diet at middle-age. *Endocrine* 21:163-167.
51. **Rasmussen DD**, Sarkar DK, Roberts JL, Gore AC 2003 Chronic daily ethanol and withdrawal: 4. Long-term changes in plasma testosterone regulation, but no effect on GnRH gene expression or plasma LH concentrations. *Endocrine* 22:143-150.
52. **Rasmussen DD** 2003 Chronic daily ethanol and withdrawal: 5. Diurnal effects on plasma thyroid hormone levels. *Endocrine* 22:329-334.
53. **Rasmussen DD** 2006 Chronic daily ethanol and withdrawal: 6. Effects on rat sympathoadrenal activity during "abstinence". *Alcohol* 38:173-177. NIH access #: 19285

54. Raskind MA, Burke BL, Crites NJ, Tapp AM, **Rasmussen DD** 2006 Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. *Neuropsychopharmacology* 32:284-288, 2007.
55. Wurst FM, **Rasmussen DD**, Hillemecher T, Kraus T, Ramskogler K, Lesch O, Bayerlein K, Schanze A, Wilhelm J, Junghanns K, Schulte T, Dammann G, Pridzun L, Wiesbeck G, Kornhuber J, Bleich S 2007 Alcoholism, craving and hormones: the role of leptin, ghrelin, prolactin and the pro-opiomelanocortin system in modulating ethanol intake. *Alcohol.Clin.Exp.Res.* 31:1963-7.
56. **Rasmussen DD**, Crites NJ, Burke BL 2008 Acoustic startle amplitude predicts vulnerability to develop post-traumatic stress hyper-responsivity and associated plasma corticosterone changes in rats. *Psychoneuroendocrinology* 33:282-291. NIH ms #: 42535
57. Walker BM, **Rasmussen DD**, Raskind MA, Koob GF 2008 The effects of α 1-noradrenergic receptor antagonism on dependence-induced increases in responding for ethanol. *Alcohol* 42: 91-97.
58. **Rasmussen DD**, Alexander LL, Raskind MA, Froehlich JC 2009 The α 1-noradrenergic receptor antagonist, prazosin, reduces alcohol drinking in alcohol-preferring (P) rats. *Alcohol.Clin.Exp.Res.* 33:264-272. NIH ms #: 84829

b) Book chapters

1. **Rasmussen DD**. 1989 In vitro perfusion of human hypothalamic and pituitary tissue. *Methods Enzymol.* 168:206-217.
2. **Rasmussen DD** 1995 Effects of nicotine on the neuroendocrine regulation of reproduction. In: *Reproductive Neuroendocrinology of Aging and Drug Abuse*, ed. by Sarkar DK, Barnes CD. CRC Press, Boca Raton. Pages 243-270.

c.) Published books, videos, software, etc.

None

d.) Other publications in non-refereed journals and letters to the editor

None

e.) Manuscripts submitted

Rasmussen DD, Kincaid CL 2009 Protracted ethanol deprivation induces increases in rat sympathoadrenal activity, visceral adiposity and plasma leptin levels which are all reversed by melatonin treatment. Submitted for publication: *Alcohol*.

Rasmussen DD, Alexander L, Malone J, Froehlich JC 2010 The α ₂-adrenergic receptor agonist, clonidine, reduces alcohol drinking in alcohol-preferring (P) rats. Submitted for publication: *Alcohol*

f.) Published Abstracts

1. **Rasmussen DD**, Malven PV. Synchronized rhythms of motor activity and plasma luteinizing hormone in ovariectomized sheep. *Fed. Proc.* 39:823, 1980.
2. **Rasmussen DD**, Malven PV. Continuous characterization of cephalic arteriovenous LH changes in ovariectomized sheep. Proceedings of the 1981 Meeting of the Society for the Study of Reproduction, Corvallis, Oregon.
3. Ishizuka B, Wilkes MM, Stewart RD, **Rasmussen DD**, Yen SSC. Increase of beta-endorphin levels in the plasma and pituitary neuro-intermediate lobe of the rat on the afternoon of proestrus. Proceedings of the 1981 Meeting of the Society for Gynecologic Investigation, Dallas.
4. **Rasmussen DD**, Stewart RD, Yen SSC. A new HPLC - electrochemical method for quantifying 3-methoxy-4-hydroxyphenylglycol in human plasma. Proceedings of the 1982 Meeting of the Federation of American Societies for Experimental Biology, New Orleans.
5. Malven PV, **Rasmussen DD**, Greene JL. Computer identification of plasma LH peaks in ovariectomized ewes during confinement stress. Proceedings of the 1982 Meeting of the American Society of Animal Science, Guelph, Ontario.
6. **Rasmussen DD**, Yen SSC. Progesterone and 20 alpha-hydroxyprogesterone stimulate the *in vitro* mediobasal hypothalamic release of LHRH. Proceedings of the 1982 Meeting of the Society for Neuro-science, Minneapolis.
7. **Rasmussen DD**, Liu JH, Yen SSC. Endogenous opioid regulation of GnRH release from the human mediobasal hypothalamus (MBH) *in vitro*. Proceedings of the 1983 Meeting of the Society for Gynecologic Investigation, Washington, D.C.
8. Key TC, Conover WB, **Rasmussen DD**, Resnik R. Neuroendocrine regulation of uterine blood flow (UBF) during late pregnancy in the ewe. Proceedings of the 1983 Meeting of the Society for Gynecologic Investigation, Washington, D.C.
9. **Rasmussen DD**, Ishizuka B, Quigley ME. Pituitary hormone release in response to food ingestion; neuroendocrine regulation by metabolic signals from gut to brain. Proceedings of the 1983 Meeting of the Endocrine Society, San Antonio.
10. **Rasmussen DD**, Liu JH, Yen SSC. Endogenous opioid regulation of GnRH release from the human mediobasal hypothalamus (MBH) *in vitro*. Proceeding of the 1983 Meeting of the Pacific Coast Fertility Society, Rancho Mirage, California.
11. **Rasmussen DD**, Liu JH, Wolf P, Yen SSC. Dopamine stimulates release of GnRH from the human mediobasal hypothalamus *in vitro*. Proceedings of the 1984 Meeting of the Society for Gynecologic Investigation, San Francisco.
12. **Rasmussen DD**, Liu JH, Wolf PL, Yen SSC. Dopamine (DA) stimulates release of beta-endorphin immunoreactivity (β -EP) from the human mediobasal hypothalamus (MBH) *in vitro*. Proceedings of the 7th International Congress of Endocrinology, Quebec, 1984.
13. Liu JH, **Rasmussen DD**, Kazer RR, Yen SSC. Alterations in ACTH pulsatile frequency in normal and pathological states. Proceedings of the 1985 Meeting of the Society for Gynecologic Investigation, Phoenix.

14. Suh BY, Liu JH, **Rasmussen DD**, Gibbs DM, Yen SSC. Oxytocin (OT) antagonizes the synergistic effect of vasopressin (VP) and ovine CRF 1-41 (oCRF) on ACTH release in normal cycling women. Proceedings of the 1985 Meeting of the Society for Gynecologic Investigation, Phoenix.
15. Gambacciani M, Yen SSC, **Rasmussen DD**. Corticotrophin releasing factor (CRF) inhibits the in vitro mediobasal hypothalamic release of GnRH. Proceedings of the 1985 Meeting of The Endocrine Society, Baltimore.
16. Gambacciani M, Yen SSC, **Rasmussen DD**. GnRH release from the mediobasal hypothalamus (MBH): in vitro regulation by oxytocin. Proceedings of the 1985 Meeting of the Society for Neuroscience, Dallas.
17. Gambacciani M, Liu JH, Swartz WH, Tueros VS, Yen SSC, **Rasmussen DD**. Intrinsic pulsatility of LH release from the human fetal pituitary in vitro. Proceedings of the 1986 Meeting of the Society for Gynecologic Investigation, Toronto.
18. Gambacciani M, Liu JH, Swartz WH, Tueros VS, Yen SSC, **Rasmussen DD**. LH release from the human fetal pituitary in vitro: evidence for an intrinsic hypophyseal pulse generating mechanism. 1986 Pacific Coast Fertility Society.
19. Gambacciani M, Yen SSC, **Rasmussen DD**. GnRH stimulates in vitro release of ACTH, beta-endorphin, and prolactin from the rat pituitary. Proceedings of the 1986 Meeting of The Endocrine Society, Anaheim.
20. Gambacciani M, Melis GB, Fioretti P, Yen SSC, **Rasmussen DD**. Dimostrazione in vitro di un meccanismo intraintraipofisario autonomo per il controllo della secrezione pulsatile di LH. I Congresso Italiano: Medicina Della Riproduzione, 1986. Republic of San Marino.
21. **Rasmussen DD**, Gambacciani M, Liu JH, Swartz WH, Tueros VS, Yen SSC. Pulsatile GnRH release from the human mediobasal hypothalamus (MBH): in vitro suppression by morphine. Proceedings of the 1987 Meeting of the Society for Neuroscience, New Orleans.
22. Liu JH, **Rasmussen DD**, Hollingsworth DR, Yen SSC. Hypercortisolism in pregnancy is associated with increased circulating concentrations of immunoreactive ACTH. Proceedings of the 1988 Meeting of the Society for Gynecologic Investigation.
23. **Rasmussen DD**, Kennedy BP, Ziegler MG, Nett TM, 1988. Endogenous opioid inhibition and facilitation of GnRH release from the median eminence in vitro: potential role of catecholamines. Proceedings of the Ninth Annual Winter Neuropeptide Conference, Breckenridge, CO.
24. Rossmannith WG, Benirschke K, Yen SSC, **Rasmussen DD**. Synchronous pulsatile release of LH and immunoreactive beta-endorphin from the human pituitary in vitro. Proceedings of the 1988 Meeting of the Endocrine Society, New Orleans.
25. **Rasmussen DD**, Kennedy BP, Ziegler MG, Nett TM. Endogenous opioid inhibition and facilitation of GnRH release from the median eminence in vitro: potential role of catecholamines. Proceedings of the 1988 Meeting of the Endocrine Society, New Orleans.
26. **Rasmussen DD**, Tueros VS, WH Swartz. Pulsatile release of immunoreactive β -endorphin (END) from the human mediobasal hypothalamus (MBH) in vitro. Proceedings of the 1989 Meeting of the Society for Gynecologic Investigation, San Diego.

27. **Rasmussen DD.** Naloxone stimulation of median eminence GnRH release *in vitro* is not modulated by estradiol (E2) or progesterone (P4). Proceedings of the 1989 Meeting of the Society for Gynecologic Investigation, San Diego.
28. **Rasmussen DD.** *In vitro*, dopamine (DA) inhibits hypothalamic GnRH release by stimulating endogenous opiate activity. Proceedings of the 1989 Meeting of the Endocrine Society, Seattle.
29. Rossmannith WG, Yen SSC, **Rasmussen DD** Sex differences in basal and GnRH-stimulated LH release from the human fetal pituitary *in vitro*. Proceedings of the 1989 Meeting of the Endocrine Society, Seattle.
30. **Rasmussen DD.** Diurnal modulation of rat hypothalamic gonadotropin-releasing hormone (GnRH) release by melatonin *in vitro*. Proceedings of the 1989 Meeting of the Society for Neuroscience, Phoenix.
31. **Rasmussen DD.** 1990 Estrogen and progesterone effects on β -endorphin and \hat{A} -MSH concentrations and ratios in individual hypothalamic nuclei. *Neuroendocrinology* 52, Suppl. 1:110.
32. **Rasmussen DD.** Dopamine/endorphin interaction in the regulation of GnRH secretion. Fourth Italian Congress of Obstetric and Gynaecological Sciences, 1990, Portoferraio, Italy.
33. **Rasmussen DD.** 1990 Lateralization of hypothalamic β -endorphin content: differential response to unilateral hemicastration. *Neuroendocrinol. Lett.* 12:232.
34. **Rasmussen DD,** Jakubowski M, Allen DL, Roberts JL 1990 Hypothalamic POMC mRNA levels during recovery from chronic estradiol: dopaminergic mechanism? *Soc. Neurosci. Abstr.* 16:1202.
35. **Rasmussen DD** 1991 Pulsatile GnRH release from the male rat isolated median eminence *in vitro*. Proceedings of the 73rd Annual Meeting of The Endocrine Society, Washington D.C.
36. **Rasmussen DD** 1991 *In vitro* perfusion for the investigation of human hypothalamic and pituitary neuroendocrine function. Proceedings of the 17th International Summer School of Brain Research: The Human Hypothalamus in Health and Disease. Amsterdam, The Netherlands.
37. Green K, **Rasmussen DD** 1991 Gonadotropin-releasing hormone (GnRH) regulates rat median eminence tyrosine hydroxylase (TH) activity *in vitro*. *Soc. Neurosci. Abstr.* 17:433.
38. **Rasmussen DD** 1991 A dopaminergic mechanism for estrogen regulation of hypothalamic endorphinergic activity? Proceedings of the International Workshop On The Neuroendocrinology of Sex Steroids: Basic Knowledge - Clinical Implications. Ulm, Germany.
39. **Rasmussen DD** Endogenous dopamine stimulates beta-endorphin release from the rat mediobasohypothalamus *in vitro*. Proceedings of the 1992 Meeting of the Endocrine Society, San Antonio, TX.
40. **Rasmussen DD** 1992 Lateralization of proopiomelanocortin mRNA content in the rat mediobasohypothalamus. *Soc. Neurosci. Abstr.* 18:991.

41. **Rasmussen DD** Effects of chronic nicotine treatment and withdrawal on neuroendocrine regulation and mediobasohypothalamic proopiomelanocortin and tyrosine hydroxylase mRNA contents. Proceedings of the 1993 Meeting of the Endocrine Society, Las Vegas.
42. **Rasmussen DD**, Toneff T 1994 Dopamine/corticotropin-releasing factor (CRF) interaction in the regulation of hypothalamic gonadotropin-releasing hormone (GnRH) secretion. Proceedings of the 25th Congress of the International Society of Psychoneuroendocrinology, Seattle, WA.
43. **Rasmussen DD**, Levin N, Lawson PT, Wilkinson CW 1995 Induction and maintenance of moderate blood alcohol levels by atraumatic pulsatile gastric infusions in "experienced" rats: transient effects on hypothalamo-pituitary-adrenal (HPA) activation. Soc.Neurosci.Abstr. 21:1241.
44. **Rasmussen DD**, Wilkinson CW 1996 Should activation of the H-P-A axis be considered characteristic of the response to moderate dosages of alcohol and other drugs of abuse? Alchol Clin Exp Res 20:12a.
45. **Rasmussen DD**, Bryant CA 1996 Potential confounding variables in alcohol liquid diet studies: aversion, habituation, dehydration. Alcohol.Clin.Exp.Res. 20:27a.
46. **Rasmussen DD**, Bryant CA, Boldt BM, Colasurdo EA, Wilkinson CW 1996 Induction and maintenance of moderate blood ethanol levels by atraumatic pulsatile gastric infusions in "experienced" rats: effects on brain opiomelanocortinerbic activity. Soc.Neurosci.Abstr. 22:700.
46. Wilkinson CW, Sarkar DK, Peskind ER, **Rasmussen DD** 1996 Dissociation between behavioral activation and neuroendocrine stress responses to cocaine. Soc.Neurosci.Abstr. 22:923.
47. Szot P, White SS, Veith RC, **Rasmussen DD** 1996 Chronic ethanol administration increases tyrosine hydroxylase mRNA, but not norepinephrine transporter mRNA in the locus coeruleus. Soc.Neurosci.Abstr. 22:468.
48. Szot P, Matsumoto AM, Veith RC, Yellon SM, **Rasmussen DD** 1997 Aging abolishes a diurnal pattern of tyrosine hydroxylase gene expression in the arcuate nucleus: effect of daily nocturnal melatonin supplementation. Endocrine Soc. Prog. and Abst. 79:374.
49. **Rasmussen DD**, Sarkar DK, Roberts JL, Gore AC 1997 Long-term daily ethanol effects on the hypothalamic-pituitary-gonadal (H-P-G) axis. Alcohol. Clin. Exp. Res. 21 (Suppl.):14a.
50. Szot P, White SS, Veith RC, **Rasmussen DD** 1997 Reduced dopamine transporter (DAT) mRNA in the ventral tegmental area (VTA) of adult rats exposed prenatally to ethanol. Alcohol. Clin. Exp. Res. 21 (Suppl.):84a.
51. **Rasmussen DD**, Boldt BM, Bryant CA, Colasurdo EA, Wilkinson CW 1997 Chronic alcohol, withdrawal, and pair-feeding effects on opiomelanocortinerbic regulation. Soc. Neurosci. Abstr. 23, 1997.
52. **Rasmussen DD**, Boldt BM, Wilkinson CW, Yellon SM, Matsumoto AM 1998 Daily melatonin administration at middle age suppresses male rat intra-abdominal fat, plasma leptin, and plasma insulin to youthful levels. Endocrine Soc Prog and Abst 80:380, 1998.

53. Wilkinson CW, Colasurdo EA, Reed SO, RW Beckham III, **Rasmussen DD**, Seeley RJ. Effects of food deprivation on concentration and molecular forms of α -melanotropin in rat hypothalamic nuclei. Soc. Neurosci. Abstr. 24:704, 1998.
54. **Rasmussen DD**, Marck B, Boldt BM, Yellon SM, Matsumoto AM. Daily melatonin administration at middle age suppresses hypothalamic proopiomelanocortin (POMC) gene expression. Soc. Neurosci. Abstr. 24:1384, 1998.
55. Mitton DR, McGillivray SA, Yellon SM, **Rasmussen DD**. Aging-associated changes in the effect of melatonin supplementation on energy regulation in rats. Soc.Neurosci.Abstr. 25:2071, 1999.
56. **Rasmussen DD**, Wilkinson CW, Mitton DR. Chronic daily alcohol and withdrawal cycles: effects on forebrain proopiomelanocortin (POMC) gene expression. Soc.Neurosci.Abstr. 25:1326, 1999.
57. **Rasmussen DD**, Mitton DR, Wilkinson CW. Persistent effects of chronic daily alcohol and withdrawal on plasma testosterone. Alcohol.Clin.Exp.Res. 23 (Suppl.):23A, 1999.
58. Wolden-Hanson T, Mitton DR, Wilkinson CW, McCants RL, Matsumoto AM, **Rasmussen DD**. Daily melatonin administration to middle-aged male rats suppresses body weight, visceral adiposity, and plasma leptin and insulin without altering food intake or total body fat. Endocrine Soc. Abstr. 81:228, 1999.
59. **Rasmussen DD**, Mitton DR. Abstinence following chronic daily ethanol/withdrawal: probable multifactorial regulation of forebrain proopiomelanocortin (POMC) gene expression. Alcohol.Clin.Exp.Res. 24 (Suppl.):83A, 2000.
60. **Rasmussen DD**, Mitton DR, Green J, Puchalski S. High anxiety and increased response to novelty during prolonged abstinence after chronic daily alcohol and withdrawal: a rat model. Alcohol.Clin.Exp.Res. 24 (Suppl.):51A, 2000.
61. **Rasmussen DD**, Mitton DR. Nocturnal excretion of 6-sulphatoxy melatonin in response to chronic daily ethanol/withdrawal. Alcohol.Clin.Exp.Res. 24 (Suppl.):123A, 2000.
62. Puchalski S, Green J, Mitton DR, **Rasmussen DD**. Melatonin effects on body weight regulation in response to high fat diet at middle age. Endocrine Soc. Abstr. 83: 469, 2001.
63. Puchalski S, Green J, Mitton DR, **Rasmussen DD**. Suppression of body weight, visceral adiposity and plasma leptin levels by melatonin administration to middle-aged male rats is independent of gonadal function. Endocrine Soc. Abstr. 83:238, 2001.
64. **Rasmussen DD**, White SS, Szot P. Chronic daily ethanol and withdrawal: effects on brain tyrosine hydroxylase (TH) and neuropeptide Y (NPY) expression during "abstinence". Soc. Neurosci. Abstr. 27:980.18, 2001.
65. **Rasmussen DD**, Wilkinson CW, Boutin NM. ACTH and corticosterone responses to acute ethanol self-administration. Alcohol.Clin.Exp.Res. 26 (Suppl.):147A, 2002.

66. **Rasmussen DD**, Chronic daily ethanol and withdrawal: diurnal effects on thyroid function. *Alcohol.Clin.Exp.Res.* 26 (Suppl.):147A, 2002.
67. **Rasmussen DD**, Wilkinson CW, Boutin NM, Puchalski S. Chronic daily ethanol and withdrawal: divergent HPA responses to acute emotional stress versus acute naloxone during "abstinence". *Alcohol.Clin.Exp.Res.* 26 (Suppl.): 147A, 2002.
68. **Rasmussen DD**, Wilkinson CW, Boutin NM. Chronic daily ethanol and withdrawal: effects on sympathoadrenal activity during "abstinence". *Soc. Neurosci. Abstr.* 28:899.15, 2002.
69. **Rasmussen DD**. Rat autonomic and behavioral responses to air-puff startle stress are enhanced during prolonged "abstinence" after chronic daily ethanol consumption. Program No. 926.4. 2003 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience.
70. **Rasmussen DD**. Decreased autonomic and behavioral sensitivity to naloxone during long-term 'abstinence' following chronic daily ethanol and withdrawal. *Alcohol.Clin.Exp.Res.* 28:55A, 2004.
71. **Rasmussen DD**, Thiruvikraman KV, Plotsky PM. Chronic daily ethanol and withdrawal: effects on brain corticotrophin-releasing factor (CRF) receptor binding during prolonged "abstinence". *Alcohol.Clin.Exp.Res.* 28:55A, 2004.
72. **Rasmussen DD**, Crites NJ. Chronic daily ethanol and withdrawal: Melatonin treatment reverses persistently increased pain sensitivity during "abstinence". Program No. 117.3. 2004 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience.
73. **Rasmussen DD**, Burke B, Crites NJ. Chronic daily ethanol and withdrawal: melatonin treatment reverses persistently increased acoustic startle response during abstinence. *Alcohol.Clin.Exp.Res.* 29:16A, 2005.
74. **Rasmussen DD**, Wilkinson CW. Chronic daily ethanol and withdrawal: sensitization of rat activation in response to ethanol during long-term abstinence. Society for Neuroscience, Program number 110.9, 2005.
75. Burke B, Crites NJ, **Rasmussen DD**. Pre-stress acoustic startle amplitude differentially predicts vulnerability to develop long term post-stress hyper-responsivity. Society for Neuroscience, Program number 58.3, 2005.
76. **Rasmussen DD**, Burke BL, Crites NJ. Daily nocturnal melatonin treatment prevents the decrease in thymus size induced by chronic ethanol consumption. Research Society on Alcoholism, Baltimore, 2006
77. **Rasmussen DD**. The brain proopiomelanocortin (POMC) system: integrating the hormones. *Alcohol.Clin.Exp.Res.* 30:103A, 2006.
78. Walker BM, **Rasmussen DD**, Raskind MA, Koob GF. Ethanol dependent animals show increased sensitivity to the effects of $\alpha 1$ adrenergic receptor antagonism on operant

self-administration of ethanol during acute withdrawal. *Soc. for Neurosci.*, Program number 292.5, 2006.

79. **Rasmussen DD**, Alexander LL, Raskind MA, Froehlich JC. The α 1-adrenergic receptor antagonist, prazosin, reduces alcohol drinking in alcohol-preferring (P) rats. *Alcohol.Clin.Exp.Res.* 31 (Suppl): 141A, 2007.

80. **Rasmussen DD**, Crites NJ, Kincaid C. Rat forebrain POMC activation during prolonged alcohol 'abstinence': reversal with melatonin treatment. *Alcohol.Clin.Exp.Res.* 31 (Suppl): 197A, 2007.

81. **Rasmussen DD**, Kincaid C. Rat sympathoadrenal activation during prolonged alcohol 'abstinence': reversal with melatonin treatment. *Alcohol.Clin.Exp.Res.* 31 (Suppl): 211A, 2007.

82. **Rasmussen DD**, Kincaid CL. Prolonged elective ethanol consumption persistently decreased forebrain proopiomelanocortin gene expression in rats: potential role of deprivations. *Soc. Neurosci.*, Prog. Number 609.10, 2007.

83. Downs JL, Aghazadeh-Sanai N, Mattison JA, Ingram DK, Wolden-Hanson T, **Rasmussen DD**, Kohama SG, Urbanski HF. The effects of age and caloric restriction (CR) on 24-hour plasma melatonin, activity and sleep rhythms in the rhesus macaque (*Macaca mulatta*). *Soc. Neurosci.*, Prog. Number 22.9, 2007.

84. **Rasmussen DD**, Alexander LL, Malone J, Froehlich JC. The α 2-adrenergic receptor agonist, clonidine, reduces alcohol drinking in alcohol-preferring (P) rats. *Alcohol.Clin.Exp.Res.* 32 (Suppl): 211A, 2008.

85. Kincaid CL, **Rasmussen DD**. Melatonin treatment during chronic ethanol withdrawal and imposed abstinence reverses rat adenohipophyseal proopiomelanocortin dysregulation. *Soc. Neurosci.* Prog. Number 846.12, 2008.

86. **Rasmussen DD**, Wolden-Hanson TH, McKelvey KM. Daily administration of melatonin reverses ethanol drinking in female ethanol-preferring (P) rats. *Soc. Neurosci.* Prog. Number 257.17, 2008.

87. **Rasmussen DD**, Federoff D, Froehlich JC. Prazosin reduces alcohol drinking in an animal model of alcohol relapse. *Alcohol. Clin. Exp. Res.* 33 (Suppl): 146A, 2009.

88. Walker B, **Rasmussen D**, Raskind M, Koob G. The effect of alpha-1 adrenergic receptor antagonism on excessive alcohol self-administration during acute withdrawal in dependent rats. *Alcohol. Clin. Exp. Res.* 33 (Suppl): 311A, 2009.

89. **Rasmussen DD**, Federoff, Froehlich JC. Prazosin reduces alcohol drinking in both non-deprived and alcohol-deprived rats selectively bred for alcohol preference. *Alcohol. Clin. Exp. Res.* 33 (Suppl): 312A, 2009.

90. Froehlich JC, Federoff D, **Rasmussen DD**. Prazosin, an α 1-adrenergic receptor antagonist, maintains continued suppression of alcohol drinking during prolonged

administration. Submitted for presentation at the 2010 annual meeting of the Research Society on Alcoholism.

91. **Rasmussen DD**, Kincaid CL. Protracted abstinence following chronic ethanol: increased locus coeruleus tyrosine hydroxylase gene expression is reversed by melatonin treatment in rats. Submitted for presentation at the 2010 annual meeting of the Research Society on Alcoholism.

92. **Rasmussen DD**, Raskind MA, Walker BM, Koob GF, Froehlich JC, Simpson TL, Saxon AJ. Translational approach to development of noradrenergic agents for treatment of alcohol dependence. Submitted for presentation at the 2010 meeting of the International Society for Biomedical Research on Alcoholism.

16. OTHER

RECENT SYMPOSIA PRESENTATIONS

Symposium lecture: "The brain proopiomelanocortin (POMC) system: integrating the hormones", World Congress on Alcohol Research, International Society for Biomedical Research on Alcohol Research, Sydney, Australia, 2006.

Rasmussen D and Koob G, organizers and co-chairs: Old Drug, New Use: Prazosin Treatment of Alcohol Use Disorders. Annual meeting of the Research Society on Alcoholism, San Diego. Alcohol. Clin. Exp. Res. 33 (Suppl): 311A, 2009.

Symposium lecture: "Translational approach to development of noradrenergic agents for treatment of alcohol dependence". Submitted for presentation at the 2010 meeting of the International Society for Brain Research on Alcoholism, Paris, France, 2010.